Success Story: Molecular Biology Researcher Achieves I-140 EB-1B Approval In Just 11 Days Through a Strong Record of Scientific Impact
Client’s Testimonial:
"I truly appreciate all the support and guidance throughout the process. Your team’s careful and highly professional handling of every step was very impressive, and it made me feel reassured during the entire process.”
On March 6th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Research Associate in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Research Associate
Country of Origin: South Korea
Approval Notice Date: March 6th, 2026
Processing Time: 11 days (Premium Processing Requested)
Case Summary:
An approval in the I-140 EB-1B category requires more than a promising research agenda. It requires persuasive evidence that the researcher has already earned international recognition in the field. In this case, our team secured approval for a molecular biology researcher whose work in vaccine production, viral conditions, and immune response analysis showed exactly that. The petition was filed with direct Premium Processing and presented a focused record of originality, influence, and sustained recognition.
Client Background and Expertise
With a Ph.D. in biomedical science and engineering, the client has built a research career at the intersection of molecular biology, virology, and immunology. Her work has focused on immune-based strategies to prevent viral infections, virus-host interactions that alter immune signaling, and the mechanisms that contribute to poor recovery after infection. At the time of filing, the client was working in the United States as a research associate, where she was designing and conducting studies on viral vaccines and therapeutics, analyzing immune responses, and collaborating on advanced research projects.
A Record of Research Excellence
The client’s qualifications include:
● 16 peer-reviewed journal articles, including 4 co-first-authored articles
● 11 abstracts, including 7 first or co-authored abstracts
● 1,183 citations
● At least 16 peer reviews
● Evidence of major funding support from prominent governmental, institutional, and industry sources
For adjudication purposes, these metrics were important not simply because of quantity, but because they showed independent validation. Her citation record reflected substantial reliance by other researchers, while her peer review activity showed that journals trusted her judgment as an expert. We also emphasized that her funding history served as another objective measure of credibility, since competitive support is typically reserved for research considered important and scientifically promising.
Recommendation Letters
The petition also included 4 recommendation letters from experts in the field. These letters helped explain the originality of the client’s work, the practical importance of her research in viral disease and immune response, and the reason her contributions had already earned international recognition.
“These citations, among the many others that [Client] has accrued, offer a clear picture of the type of sophisticated research she is producing and its effects in the field. As such, it is critical that she be permitted to continue her research to the greater benefit of the U.S.”
Approval Outcome
By showing that the client’s work had influenced the field in concrete, documentable ways, we established that she met the high standard for I-140 EB-1B classification. The petition was approved, and we are honored to have supported the client in this important milestone.